Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
We are advancing our commercial preparation activities in anticipation of a potential launch of OLC later this year, to help provide an important treatment option to patients with chronic kidney disease (CKD) on dialysis who continue to struggle with hyperphosphatemia. The NDA is supported by data from three clinical studies, multiple preclinical studies, and chemistry, manufacturing and controls (CMC) data
We use the model to investigate changes resulting from a 9-day course of dexamethasone treatment
2:24-md-03094, 5/8/24.
Apr 7 2011;2(2):123-131
This may reduce side effect risks
US$ 24.26
US$ 24.83
US$ 26.25
